Welcome to the Workz Community. www.shippingworkz.com, www.logisticsworkz.com, and www.supplychainworkz.com are industry-specific portals for these dynamic industries. They contain breaking news, industry perspective, networking, career opportunities and learning & development. Be a part of the Workz community today!
EUGM 2013 - Attila Szabo (ChemAxon) - Collaborate and search in SharePoint wi...ChemAxon
This document discusses how ChemAxon's JChem product allows users to collaborate and search within SharePoint. JChem for SharePoint allows users to insert chemical structures into SharePoint sites, documents, and lists. It also enables searching for structures within SharePoint. Structures can be edited within SharePoint and calculated properties like logP values will be displayed. Future plans include integrating additional ChemAxon tools like Marvin JS and supporting SharePoint 2013 and external databases.
EUGM 2013 - Steve Hajkowski (Thomson Reuters): Patent analytics - what can Ma...ChemAxon
The presentation will address the variety of industry and scientific trends that patent and more particularly Markush structure data can demonstrate. Case studies will show how structural and other patent features can help make sense of large and apparently disparate sets of data.
USUGM 2014 - Zhengwei Peng (Merck): Construction of a vast virtual chemical s...ChemAxon
With the addition of a molecular similarity search capability, the ChemAxon Markush Search platform is now capable of performing Exact, Sub-Structure, and Similarity searches. Those three types of searches are commonly used by drug discovery chemists to search against molecular databases containing up to 109 molecules. This effectively places very large (1012 – 1018) chemical compound spaces, real or virtual, which can be expressed as Markush cores in combinations with R-group fragments, at the fingertips of drug discovery chemists for ideal generation, data mining, lead hopping, as well as analysis related to IP positions. This talk will cover a recent work at Merck to construct a virtual chemical space powered by ChemAxon’s search engine and a few poetical applications planned.
In the last two years, we transitioned the most-asked-for features from our successful MarvinSketch desktop application to a new lightweight web component: Marvin JS. However this was not a simple copy/pasting of features. The challenges of JavaScript technology, the possibilities of touch screen drawing and the benefits of hindsight made us re-imagine even the most basic drawing features to create a clean, straight forward user-oriented tool.
USUGM 2014 - Aurora Costache (ChemAxon): Reporting & Sharing in Evolution of ...ChemAxon
ChemAxon has been developing chemical data management tools, toolkits and applications for 16 years, primarily to the life science industry. Over this time, changes in the industry and technology have led change in our technology and how we work with clients. This talk outlines the ChemAxon functionality, breaking the topic down into processes scientists care about (creation, storage, analysis & reporting), highlights developments and our response to the opportunities in this changing environment.
Marvin JS is a novel light-weight chemical editor suitable for generating standard chemical structures without the need for installing Java, designed by ChemAxon. It provides all the essential features for quick and easy structure drawing as well as flexible editing options for molecular manipulations. Pearson Education is partnering with ChemAxon to develop a custom educational version of Marvin JS to be used in Pearson’s chemical tutorial platform, MasteringChemistry.
This educational version of Marvin JS separates out various tools into “presets” to match specific answer types that Pearson authors have designed – skeletal 2D problems, skeletal 3D problems and mechanism problems. For example, tools necessary for drawing mechanisms will only be available for those problems that ask the student to draw a mechanism. In additional, authors will be able to set specific initialization parameters for individual problems such as “show lone pairs” or “show R,S labels”. This higher level of feature control allows authors to better regulate what students are able to see and able to do in the drawing tool, minimizing opportunities for mistakes (using the wrong templates for example) or cheating (using R,S labels to answer a stereochemistry question). Pearson will offer this custom version of Marvin JS for Organic and General Chemistry drawing items both for desktop and for mobile beginning in January 2014.
USUGM 2014 - Árpád Figyelmesi (ChemAxon): Working Effectively with Complex Ma...ChemAxon
This document discusses techniques for working with complex Markush structures. It describes Markush representations including R-groups, atom lists, and bond lists. It also discusses recent developments such as R-group bridging, the Markush Editor software for defining and viewing structures, and Markush overlap analysis for calculating overlapping chemical spaces without enumeration. Future plans are outlined as well, such as adding group properties, standardization, and similarity search capabilities to analysis of Markush structures.
USUGM 2014 - Eufrozina Hoffmann (ChemAxon): Balancing usability and power for...ChemAxon
Marvin JS is the newest member of the Marvin product family. The chemical smartness of MarvinSketch has been transferred to this clean, straight-forward, user-oriented web component. This transfer does not mean that developing Marvin JS was a simple copy/paste of features. The extensive potential in the JavaScript technology, especially its adoptability on touch devices, drove us to re-imagine even the most basic drawing features. During the development we tried to find the balance between the robust chemical knowledge and the intuitive usage.
EUGM 2014 - Richard Bolton (GlaxoSmithKline): GlaxoSmithKline: 5 years with ...ChemAxon
GlaxoSmithKline began using ChemAxon tools across its enterprise systems in late 2009. A selection of presentations from previous UGM which reflect the increasing usage and show the developing relationship between the two companies will be highlighted and key status updated. A new use for ChemAxon tools in Enterprise Search will be presented.
EUGM 2013 - Jon Patterson (ChemAxon) ChemAxon Platform for Scientists ChemAxon
As scientists we need to deal with inordinate amounts of data every day: we generate, retrieve and manipulate new data as part of our job. Simple excel worksheets are not the solution in the modern era of drug discovery, development and beyond. In this session learn how you can use and integrate ChemAxon’s tools to solve your day-by-day tasks more quickly and efficiently. Whether you prefer a desktop, web-based or touch screen application, we have a solution. Learn how to manipulate your data using Instant JChem (on your desktop or via Web layer) or draw sophisticated queries using Marvin or our new addition Marvin for Java Script (Marvin JS) to reduce the search times, visualize your data in 3D using Marvin Space, export and explore chemistry with the Ubiquitous Excel using the JChem for Excel plugin and share ideas and data with you colleagues and/or collaborators using Crais Board. Integrate our tools in Pipeline Pilot and Knime protocols and generate new data to expedite your processes. Analyze your data using Spotfire through Instant JChem. Also learn how our newest addition, Plexus, will help you do you tasks on desktop using web technology.
EUGM 2013 - Sergio H. Rotstein (Pfizer): What about the “big guys”? The emerg...ChemAxon
The recent increase in utilization of complex macromolecules such as Antibody-Drug Conjugates (ADCs) as therapeutic agents has revealed a substantial gap in the biopharmaceutical industry’s portfolio of informatics tools and methods, most of which were designed to work primarily with either small molecules or unmodified and unconjugated amino acid and nucleotide sequences. The Hierarchical Editing Language for Macromolecules (HELM), along with a software toolkit that leverages that language was developed by Pfizer researchers to address this gap (see J. Chem. Inf. Model 2012, 52, 2796-2806). HELM and related technologies such as SCSR (Self-Contained Sequence Representation, see: JChem Inf Model. 2011 51, 2186-208.), enable the representation of unnatural, conjugated or otherwise modified building blocks in biopolymers such as oligonucleotides, peptides, proteins and ADCs. HELM is being released into the Open Source and the Pistoia Alliance has initiated a project that has the goals of (1) facilitating this release, (2) adopting HELM as an industry standard for the manipulation and exchange of complex biomolecule data, and (3) setting up the organizational infrastructure to govern the future development of the standard. Given the recent FDA approval of the Antibody Drug Conjugate Kadcyla (Ado-Trastuzumab Emtansine) for Her2-Positive Metastatic Breast Cancer, one can reasonably assume that standards such as HELM and associated software tools will play an increasingly prominent role as part of the modern drug discovery informatics arsenal.
EUGM 2013 - Michael Dippolito (Deltasoft): Great Migrations! – Approaches to ...ChemAxon
Many research teams are facing chemistry data migrations in the coming months due to legacy system retirements and/or the opportunity to move to new informatics platforms. Some approaches, case studies, and experiences will be shared on migrating chemistry data between vendor technologies, with a focus on moving to ChemAxon cartridge technology.
EUGM15 - Zoltán Simon (Printnet): Drug Profile Matching - Drug Discovery by P...ChemAxon
Most drugs exert their effects via multi-target interactions, as hypothesized by polypharmacology. Here we introduce Drug Profile Matching (DPM) which is able to relate complex drug-protein interaction profiles with effect and target profiles. Structural data and registered effect profiles of all small-molecule drugs were collected and interactions to a series of non-target protein binding sites of each drug were calculated. Statistical analyses confirmed close relationships between the studied 177 effect and 77 target categories and the in silico generated interaction profiles of cca. 1,200 FDA-approved small-molecule drugs. Receiver Operating Characteristic analysis and 10-fold cross-validation was performed to assess the accuracy and robustness of the method. Based on the found relationships, the effect and target profiles of drugs can be revealed in their entirety, and hitherto uncovered effects and targets can be predicted in a systematic manner.
In order to investigate the predictive power of DPM, four effect categories (PPAR agonist, angiotensin-converting enzyme inhibitor, cyclooxygenase inhibitor and dopamine agent) were selected and predictions in the set of the FDA-approved small-molecule drugs were verified by literature analysis and experimental tests.
Moreover, a large set consisting of 600,000 druglike molecules was selected from a database of 50 million compounds and their interaction profiles were generated. Based on these profiles and chemical similarity considerations, predictions were calculated and tested experimentally to find new candidates that are chemically dissimilar to the reference drugs.
EUGM 2013 - Andrea de Souza (Broad Institute): Setting the stage for the “SD”...ChemAxon
Building on the success of the Molecular Libraries Program (MLP), the Broad Institute MLP team is co-leading with the National Center for Advancing Translational Sciences (NCATS) an NIH-sponsored project across 7 institutions to augment the data in PubChem with the creation of the Bioassay Research Database (BARD). The BARD platform standardizes the representation of bioassays in a next-generation repository and provides a user-friendly interface that supports sophisticated queries and data mining. Data originating from publicly-funded chemical biology research efforts will be presented with appropriate context including structured assay and result annotations. These annotations use relevant ontologies including, for example, the BioAssay Ontology, Gene Ontology, and the Unit Ontology. We simplified the representation of ontologies into a hierarchical data dictionary to enable data producers to more easily create and upload projects, assays, and results, while creating two separate user interfaces for data consumers. The BARD WebQuery Interface leverages a Google-like interface with auto-suggest functionality for complex queries, such as retrieval of all assays, and results for biological pathways such as “DNA repair” or “oxidative stress”; presentation of this information in a rich-user interface that includes spreadsheet support for structure-activity relationship analyses. Compounds, projects, and assays can be exported into an Amazon-like query cart for refining queries, and additional computations can be executed on datasets via community-developed plug-ins including promiscuity analyses via the BioActivity Data Associative Promiscuity Pattern Learning Engine (BADAPPLE) and a CYP450 metabolism site prediction plugin (hgp://www.farma.ku.dk/smartcyp/) using 2D structure fingerprints. Integration between the WebQuery and Desktop clients enables power users to initiate analyses in WebQuery and gain more insight via the Desktop client.
Lastly, as industry and academia work together to innovate in small-molecule therapeutics, we have created an initial specification for the Assay Definition Standard. This standard through the Assay Definition Format has been used as the medium of data file transfer for data upload. We expect that the Chemical Biology community now has an opportunity to leverage this standard to routinely transfer assay and result data within and between information systems and organizations.
This presentation will highlight the BARD platform with a focus on representing the cumulative body of work that exploits the ChemAxon toolkit.
Welcome to the Workz Community. www.shippingworkz.com, www.logisticsworkz.com, and www.supplychainworkz.com are industry-specific portals for these dynamic industries. They contain breaking news, industry perspective, networking, career opportunities and learning & development. Be a part of the Workz community today!
EUGM 2013 - Attila Szabo (ChemAxon) - Collaborate and search in SharePoint wi...ChemAxon
This document discusses how ChemAxon's JChem product allows users to collaborate and search within SharePoint. JChem for SharePoint allows users to insert chemical structures into SharePoint sites, documents, and lists. It also enables searching for structures within SharePoint. Structures can be edited within SharePoint and calculated properties like logP values will be displayed. Future plans include integrating additional ChemAxon tools like Marvin JS and supporting SharePoint 2013 and external databases.
EUGM 2013 - Steve Hajkowski (Thomson Reuters): Patent analytics - what can Ma...ChemAxon
The presentation will address the variety of industry and scientific trends that patent and more particularly Markush structure data can demonstrate. Case studies will show how structural and other patent features can help make sense of large and apparently disparate sets of data.
USUGM 2014 - Zhengwei Peng (Merck): Construction of a vast virtual chemical s...ChemAxon
With the addition of a molecular similarity search capability, the ChemAxon Markush Search platform is now capable of performing Exact, Sub-Structure, and Similarity searches. Those three types of searches are commonly used by drug discovery chemists to search against molecular databases containing up to 109 molecules. This effectively places very large (1012 – 1018) chemical compound spaces, real or virtual, which can be expressed as Markush cores in combinations with R-group fragments, at the fingertips of drug discovery chemists for ideal generation, data mining, lead hopping, as well as analysis related to IP positions. This talk will cover a recent work at Merck to construct a virtual chemical space powered by ChemAxon’s search engine and a few poetical applications planned.
In the last two years, we transitioned the most-asked-for features from our successful MarvinSketch desktop application to a new lightweight web component: Marvin JS. However this was not a simple copy/pasting of features. The challenges of JavaScript technology, the possibilities of touch screen drawing and the benefits of hindsight made us re-imagine even the most basic drawing features to create a clean, straight forward user-oriented tool.
USUGM 2014 - Aurora Costache (ChemAxon): Reporting & Sharing in Evolution of ...ChemAxon
ChemAxon has been developing chemical data management tools, toolkits and applications for 16 years, primarily to the life science industry. Over this time, changes in the industry and technology have led change in our technology and how we work with clients. This talk outlines the ChemAxon functionality, breaking the topic down into processes scientists care about (creation, storage, analysis & reporting), highlights developments and our response to the opportunities in this changing environment.
Marvin JS is a novel light-weight chemical editor suitable for generating standard chemical structures without the need for installing Java, designed by ChemAxon. It provides all the essential features for quick and easy structure drawing as well as flexible editing options for molecular manipulations. Pearson Education is partnering with ChemAxon to develop a custom educational version of Marvin JS to be used in Pearson’s chemical tutorial platform, MasteringChemistry.
This educational version of Marvin JS separates out various tools into “presets” to match specific answer types that Pearson authors have designed – skeletal 2D problems, skeletal 3D problems and mechanism problems. For example, tools necessary for drawing mechanisms will only be available for those problems that ask the student to draw a mechanism. In additional, authors will be able to set specific initialization parameters for individual problems such as “show lone pairs” or “show R,S labels”. This higher level of feature control allows authors to better regulate what students are able to see and able to do in the drawing tool, minimizing opportunities for mistakes (using the wrong templates for example) or cheating (using R,S labels to answer a stereochemistry question). Pearson will offer this custom version of Marvin JS for Organic and General Chemistry drawing items both for desktop and for mobile beginning in January 2014.
USUGM 2014 - Árpád Figyelmesi (ChemAxon): Working Effectively with Complex Ma...ChemAxon
This document discusses techniques for working with complex Markush structures. It describes Markush representations including R-groups, atom lists, and bond lists. It also discusses recent developments such as R-group bridging, the Markush Editor software for defining and viewing structures, and Markush overlap analysis for calculating overlapping chemical spaces without enumeration. Future plans are outlined as well, such as adding group properties, standardization, and similarity search capabilities to analysis of Markush structures.
USUGM 2014 - Eufrozina Hoffmann (ChemAxon): Balancing usability and power for...ChemAxon
Marvin JS is the newest member of the Marvin product family. The chemical smartness of MarvinSketch has been transferred to this clean, straight-forward, user-oriented web component. This transfer does not mean that developing Marvin JS was a simple copy/paste of features. The extensive potential in the JavaScript technology, especially its adoptability on touch devices, drove us to re-imagine even the most basic drawing features. During the development we tried to find the balance between the robust chemical knowledge and the intuitive usage.
EUGM 2014 - Richard Bolton (GlaxoSmithKline): GlaxoSmithKline: 5 years with ...ChemAxon
GlaxoSmithKline began using ChemAxon tools across its enterprise systems in late 2009. A selection of presentations from previous UGM which reflect the increasing usage and show the developing relationship between the two companies will be highlighted and key status updated. A new use for ChemAxon tools in Enterprise Search will be presented.
EUGM 2013 - Jon Patterson (ChemAxon) ChemAxon Platform for Scientists ChemAxon
As scientists we need to deal with inordinate amounts of data every day: we generate, retrieve and manipulate new data as part of our job. Simple excel worksheets are not the solution in the modern era of drug discovery, development and beyond. In this session learn how you can use and integrate ChemAxon’s tools to solve your day-by-day tasks more quickly and efficiently. Whether you prefer a desktop, web-based or touch screen application, we have a solution. Learn how to manipulate your data using Instant JChem (on your desktop or via Web layer) or draw sophisticated queries using Marvin or our new addition Marvin for Java Script (Marvin JS) to reduce the search times, visualize your data in 3D using Marvin Space, export and explore chemistry with the Ubiquitous Excel using the JChem for Excel plugin and share ideas and data with you colleagues and/or collaborators using Crais Board. Integrate our tools in Pipeline Pilot and Knime protocols and generate new data to expedite your processes. Analyze your data using Spotfire through Instant JChem. Also learn how our newest addition, Plexus, will help you do you tasks on desktop using web technology.
EUGM 2013 - Sergio H. Rotstein (Pfizer): What about the “big guys”? The emerg...ChemAxon
The recent increase in utilization of complex macromolecules such as Antibody-Drug Conjugates (ADCs) as therapeutic agents has revealed a substantial gap in the biopharmaceutical industry’s portfolio of informatics tools and methods, most of which were designed to work primarily with either small molecules or unmodified and unconjugated amino acid and nucleotide sequences. The Hierarchical Editing Language for Macromolecules (HELM), along with a software toolkit that leverages that language was developed by Pfizer researchers to address this gap (see J. Chem. Inf. Model 2012, 52, 2796-2806). HELM and related technologies such as SCSR (Self-Contained Sequence Representation, see: JChem Inf Model. 2011 51, 2186-208.), enable the representation of unnatural, conjugated or otherwise modified building blocks in biopolymers such as oligonucleotides, peptides, proteins and ADCs. HELM is being released into the Open Source and the Pistoia Alliance has initiated a project that has the goals of (1) facilitating this release, (2) adopting HELM as an industry standard for the manipulation and exchange of complex biomolecule data, and (3) setting up the organizational infrastructure to govern the future development of the standard. Given the recent FDA approval of the Antibody Drug Conjugate Kadcyla (Ado-Trastuzumab Emtansine) for Her2-Positive Metastatic Breast Cancer, one can reasonably assume that standards such as HELM and associated software tools will play an increasingly prominent role as part of the modern drug discovery informatics arsenal.
EUGM 2013 - Michael Dippolito (Deltasoft): Great Migrations! – Approaches to ...ChemAxon
Many research teams are facing chemistry data migrations in the coming months due to legacy system retirements and/or the opportunity to move to new informatics platforms. Some approaches, case studies, and experiences will be shared on migrating chemistry data between vendor technologies, with a focus on moving to ChemAxon cartridge technology.
EUGM15 - Zoltán Simon (Printnet): Drug Profile Matching - Drug Discovery by P...ChemAxon
Most drugs exert their effects via multi-target interactions, as hypothesized by polypharmacology. Here we introduce Drug Profile Matching (DPM) which is able to relate complex drug-protein interaction profiles with effect and target profiles. Structural data and registered effect profiles of all small-molecule drugs were collected and interactions to a series of non-target protein binding sites of each drug were calculated. Statistical analyses confirmed close relationships between the studied 177 effect and 77 target categories and the in silico generated interaction profiles of cca. 1,200 FDA-approved small-molecule drugs. Receiver Operating Characteristic analysis and 10-fold cross-validation was performed to assess the accuracy and robustness of the method. Based on the found relationships, the effect and target profiles of drugs can be revealed in their entirety, and hitherto uncovered effects and targets can be predicted in a systematic manner.
In order to investigate the predictive power of DPM, four effect categories (PPAR agonist, angiotensin-converting enzyme inhibitor, cyclooxygenase inhibitor and dopamine agent) were selected and predictions in the set of the FDA-approved small-molecule drugs were verified by literature analysis and experimental tests.
Moreover, a large set consisting of 600,000 druglike molecules was selected from a database of 50 million compounds and their interaction profiles were generated. Based on these profiles and chemical similarity considerations, predictions were calculated and tested experimentally to find new candidates that are chemically dissimilar to the reference drugs.
EUGM 2013 - Andrea de Souza (Broad Institute): Setting the stage for the “SD”...ChemAxon
Building on the success of the Molecular Libraries Program (MLP), the Broad Institute MLP team is co-leading with the National Center for Advancing Translational Sciences (NCATS) an NIH-sponsored project across 7 institutions to augment the data in PubChem with the creation of the Bioassay Research Database (BARD). The BARD platform standardizes the representation of bioassays in a next-generation repository and provides a user-friendly interface that supports sophisticated queries and data mining. Data originating from publicly-funded chemical biology research efforts will be presented with appropriate context including structured assay and result annotations. These annotations use relevant ontologies including, for example, the BioAssay Ontology, Gene Ontology, and the Unit Ontology. We simplified the representation of ontologies into a hierarchical data dictionary to enable data producers to more easily create and upload projects, assays, and results, while creating two separate user interfaces for data consumers. The BARD WebQuery Interface leverages a Google-like interface with auto-suggest functionality for complex queries, such as retrieval of all assays, and results for biological pathways such as “DNA repair” or “oxidative stress”; presentation of this information in a rich-user interface that includes spreadsheet support for structure-activity relationship analyses. Compounds, projects, and assays can be exported into an Amazon-like query cart for refining queries, and additional computations can be executed on datasets via community-developed plug-ins including promiscuity analyses via the BioActivity Data Associative Promiscuity Pattern Learning Engine (BADAPPLE) and a CYP450 metabolism site prediction plugin (hgp://www.farma.ku.dk/smartcyp/) using 2D structure fingerprints. Integration between the WebQuery and Desktop clients enables power users to initiate analyses in WebQuery and gain more insight via the Desktop client.
Lastly, as industry and academia work together to innovate in small-molecule therapeutics, we have created an initial specification for the Assay Definition Standard. This standard through the Assay Definition Format has been used as the medium of data file transfer for data upload. We expect that the Chemical Biology community now has an opportunity to leverage this standard to routinely transfer assay and result data within and between information systems and organizations.
This presentation will highlight the BARD platform with a focus on representing the cumulative body of work that exploits the ChemAxon toolkit.
2. Safe Harbor
Safe harbor statement under the Private Securities Litigation Reform Act of 1995: This presentation
may contain forward-looking statements that involve risks, uncertainties, and assumptions. If any such
uncertainties materialize or if any of the assumptions proves incorrect, the results of salesforce.com,
inc. could differ materially from the results expressed or implied by the forward-looking statements we
make. All statements other than statements of historical fact could be deemed forward-looking,
including any projections of subscriber growth, earnings, revenues, or other financial items and any
statements regarding strategies or plans of management for future operations, statements of belief,
any statements concerning new, planned, or upgraded services or technology developments and
customer contracts or use of our services.
The risks and uncertainties referred to above include – but are not limited to – risks associated with
developing and delivering new functionality for our service, our new business model, our past
operating losses, possible fluctuations in our operating results and rate of growth, interruptions or
delays in our Web hosting, breach of our security measures, the immature market in which we
operate, our relatively limited operating history, our ability to expand, retain, and motivate our
employees and manage our growth, new releases of our service and successful customer deployment,
and utilization and selling to larger enterprise customers. Further information on potential factors that
could affect the financial results of salesforce.com, inc. is included in our quarterly report on Form 10-
Q filed on July 31, 2007 and in other filings with the Securities and Exchange Commission. These
documents are available on the SEC Filings section of the Investor Information section of our Web site.
Any unreleased services or features referenced in this or other press releases or public statements are
not currently available and may not be delivered on time or at all. Customers who purchase our
services should make the purchase decisions based upon features that are currently available.
Salesforce.com, inc. assumes no obligation and does not intend to update these forward-looking
statements.
6. 業界で幅広く認められている革新性
セールスフォース・ドットコムはCRM業界の「リーダー」に
2007 MM RI 2007 2007
Technology Awards JiIT IT Awards ASP IT Awards
CRM リーダー Top Ten Disruptors Top 100 Innovative Technology of
of 2006 Companies the Year
Best CRM & Market Leader 2006 Product
On-Demand Platform Enterprise CRM of the Year
“ 今後企業・組織が導入する
新しい SFA の大部分は、 Leader & #11 Fifty People World-Class
Visionary Who Matter Most Innovator Award
SaaS ベースになるでしょう
”
Top 10 Entrepreneurs #7 #7 Top 100 Most
& Cool Company Influential People
Top 40
32. Infrastructure as a Service
Platform as a Service (PaaS)
100M+
トランザクション/日
1億ドルの投資
平均レスポンスタイム
225/ミリ秒 ミラリングされた2つのデータセンター
拡張性のあるアーキテクチャー
900,000+ キャパシティープラニング
のユーザ
ディザスターリカバリー
• SAS 70 Type II • IP Restricted Access Option
• SysTrust Certified • Flexible Single Sign-on option
• Network and Physical Security • Integrated Two Factor Authentication
33. Globalization as a Service
Platform as a Service (PaaS)
顧客数 35,300人 15 言語に対応
すべての主要通貨に対応
世界での導入数 23,709 件 トランスレーションワークベンチ
AppExchange上での
グローバルアプリケーションのパッケージ化
“ セールスフォース・ドットコムにより、世界各国の支社のレポジト
リが１つに集約され、グローバル・レポジトリが実現しました
”
34. 当社のサービス上に、御社のデータベースを
Platform as a Service (PaaS)
任意テーブルの作成
600万件以上の 任意フィールドの追加
カスタマイズ 任意リレーションシップ構築
1秒あたりのSQL実行回数が セキュリティおよび共有
160,000件 監査ログの自動追跡
自動チューニング
ユーザの追加は無限 自動バックアップ
自動アップグレード
“ セールスフォース・ドットコムのアプリケーションは、製造業界における弊社特有のニー
ズに合わせて容易にカスタマイズができます。他には類を見ないソリューションです。
”
35. Integration as a Service - サービスとしてのインテグレーション
Platform as a Service (PaaS)
月間10億 Web サービス API
50%がAPI トランザクション SAP & Oracle インテグレーション
オンデマンドSOA
総計187億 バックエンドおよびデスクトップとの
APIトランザクション総計 インテグレーション
“ セールスフォース･ドットコムのアーキテクチャは、当社のあらゆる特性を持つビジネスやマー
ケットに対応しながら、One Dupont SAP transaction engine とともに運用できます。これ
は非常にパワフルな組み合わせです
” Bob Ridout, CIO
36. Workflow as a Service - サービスとしてのワークフロー
Platform as a Service (PaaS)
宣言的
59,200 ワークフロー定義 プログラミング可能
A B D 承認
インテリジェント
700万件 自動処理タスク 時刻指定によるトリガー
C 計算項目
メールによるトリガー
37. Logic as a Service : 当社サービス上で実行されるコード
Platform as a Service (PaaS)
